BSc, MSc, PhD
Senior Research Associate
Martin Philpott was educated at the University of Auckland, gaining his PhD in 2001 at the Auckland Cancer Society Research Centre, working on the preclinical development of the anticancer agent Vadimezan. He then joined the Discipline of Nutrition in Faculty of Medical and Health Sciences at University of Auckland, examining the anticancer properties of natural flavonoids. In 2004, he became a founding member of Nutrigenomics New Zealand, a consortium of the University of Auckland and several Crown Research Institutes, with the aim of tailoring New Zealand foods to people’s genes, with initial proof of principle studies targeting inflammatory bowel disease. In 2009, he moved to the Structural Genomics Consortium, University of Oxford, to develop potent and selective small molecule inhibitors of proteins involved in epigenetic processes. He joined the group of Prof. Oppermann at the Botnar Research Centre in 2014.
Martin's research aims to systematically identify epigenetic factors that underpin the transition from mesenchymal stem cells to bone forming osteoblasts, in the context of inflammation and aging that typifies rheumatoid arthritis. The project makes extensive use of antisense and small molecule inhibitors coupled to next generation sequencing.